Correspondence to Dr Hideo Ohuchi, Department of Paediatric Cardiology, National Cerebral and Cardiovascular Centre, 5-7-1, Fujishiro-dai, Suita, Osaka 565-8565, Japan; hohuchi{at}hsp.ncvc.go.jp ...

Definitions of hypoxaemia, hypoxia, type 1 respiratory failure and hyperoxaemia Definition of hypercapnia and type 2 respiratory failure Definition of acidosis (respiratory acidosis and metabolic ...

Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos. Cytokinetics has won FDA approval of its ...

An ABG test checks how well your lungs and kidneys work by measuring oxygen and carbon dioxide in your blood. This test helps doctors know if your body has an acid-base balance issue and if treatment ...

本刊编辑推荐：为解决当前基于血红蛋白（Hb）的输血策略在稳定期癌症贫血患者中可能无法准确反映组织氧合状态的问题，研究人员开展了一项前瞻性观察研究，主题为评估氧摄取率（O2ER）等生理学指标作为替代输血触发因素的可行性。研究结果表明，基线O2ER ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical ...

The shares of biotechnology firm Cytokinetics are approaching what may be one of the most consequential weeks in the company’s recent timeline. Investor attention is intensely focused on an imminent ...

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Cytokinetics今日宣布，美国FDA已批准Myqorzo（aficamten）上市，用于治疗有症状的梗阻性肥厚型心肌病（oHCM）成人患者。值得一提的是，这款药物在今年年初曾被行业媒体Evaluate列为有望在2025年获批的潜在重磅疗法。 本次批准基于关键性3期临床试验SEQUOIA-HCM的积极 ...